FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCardiff Oncology, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CRDF
Cardiff Oncology, Inc. Stock AnalysisComprehensive stock analysis for Cardiff Oncology, Inc. (CRDF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCRDF
CRDF
Cardiff Oncology, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CRDF
Home🔹Stocks🔹Cardiff Oncology, Inc.

Cardiff Oncology, Inc.

🇺🇸CRDF•NASDAQ

Cardiff Oncology, Inc.

🇺🇸CRDF•NASDAQ
Market cap
$59.54M
Sentiment

Your view on CRDF

Mkt Cap
$59.54M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cardiff Oncology, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Mark Erlander
Headquarters
11055 Flintkote Avenue, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Mark Erlander
Headquarters
11055 Flintkote Avenue, San Diego, CA, US
Description

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California.

Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers.

The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

Fair value for Cardiff Oncology, Inc. from FRC's valuation model, read against the market price. CRDF last traded at $0.77; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Cardiff Oncology, Inc.. Starting points for Cardiff Oncology, Inc.: EPS -$0.59, beta 1.56 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Cardiff Oncology, Inc.. Cardiff Oncology, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Cardiff Oncology, Inc.. Trailing twelve-month EPS for Cardiff Oncology, Inc. stands at -$0.59. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

As of Nov 12, 2026 · USD

1-Year Price Target

$2.00average of analysts' targets

 

Low

$2.00

Median

$2.00

High

$2.00

Average target

Analyst Ratings

Buyconsensus of 15 analysts
  • Strong Buy0
  • Buy8
  • Hold6
  • Sell1
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrSep 2026Next QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$0.14-$0.13-$0.58-$0.61
Low estimate-$0.15-$0.15-$0.62-$0.81
High estimate-$0.13-$0.11-$0.54-$0.35
No. of analysts4444
Year-ago EPS-$0.17-$0.11-$0.69—
Growth+18.8%-21.4%+16.3%—

Revenue Estimate

RevenueCurrent QtrSep 2026Next QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$81429.00$86429.00$292143.00$320833.00
Low estimate$37013.00$36012.00$94239.00$125816.00
High estimate$111039.00$115238.00$424078.00$459231.00
No. of analysts5565
Year-ago revenue$120000.00$243000.00$593000.00—
Growth-32.1%-64.4%-50.7%—
Recent analyst actions15 rating and price-target changes, latest Sep 15, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Cardiff Oncology, Inc.. Cardiff Oncology, Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Cardiff Oncology, Inc. valued side by side against its closest peers. Cardiff Oncology, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Cardiff Oncology, Inc., and how their positions are changing. At a $59.5M market value, institutional positions materially move Cardiff Oncology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Cardiff Oncology, Inc. executives and directors. Shares of Cardiff Oncology, Inc. have traded between $1.90 and $5.64 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Cardiff Oncology, Inc.. Coverage tracks Cardiff Oncology, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cardiff Oncology, Inc.

Peer companies

  • CRBPCorbus Pharmaceuticals Holdings, Inc.
  • ELTXElicio Therapeutics, Inc.
  • IPHAInnate Pharma S.A.
  • MISTMilestone Pharmaceuticals Inc.
  • MOLNMolecular Partners AG
  • PEPGPepGen Inc.

More Biotechnology companies

  • AMPEAmpio Pharmaceuticals, Inc.
  • ANABAnaptysBio, Inc.
  • ANEBAnebulo Pharmaceuticals, Inc.
  • ANIXAnixa Biosciences, Inc.
  • ANLAdlai Nortye Ltd. American Depositary Shares
  • ANNXAnnexon, Inc.
  • ANR.AXAnatara Lifesciences Ltd
  • ANROAlto Neuroscience, Inc.
  • ANTHAnthera Pharmaceuticals, Inc.
  • ANTIAntigenics, Inc.
  • ANTXAN2 Therapeutics, Inc.
  • ANVSAnnovis Bio, Inc.

ETFs holding Cardiff Oncology, Inc.

Largest holders, then the funds most concentrated in CRDF · % = share of the fund

  • VTIVanguard Total Stock Market ETF0.00%
  • VXFVanguard Extended Market ETF0.00%
  • IWCiShares Micro-Cap ETF0.01%
  • VUN.TOVanguard U.S. Total Market Index ETF0.00%
CRDF Analysis
Fair
Past1
Growth2
Health5
Profit1
Value1

News

Latest Market News